Parnassus Investments LLC Lowers Stake in IQVIA Holdings Inc. $IQV

Parnassus Investments LLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 183,977 shares of the medical research company’s stock after selling 15,575 shares during the period. Parnassus Investments LLC owned approximately 0.11% of IQVIA worth $41,470,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA in the 4th quarter worth $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth $27,000. Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth $27,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of IQVIA in the 3rd quarter worth $30,000. Finally, Activest Wealth Management boosted its holdings in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $174.00 to $213.00 in a report on Monday, March 9th. HSBC set a $210.00 price objective on shares of IQVIA in a research report on Wednesday, June 3rd. Mizuho set a $215.00 target price on shares of IQVIA in a report on Monday, February 23rd. Truist Financial decreased their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Finally, Morgan Stanley set a $225.00 price target on shares of IQVIA in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $224.13.

IQVIA Stock Down 0.7%

Shares of IQV stock opened at $180.89 on Friday. The stock has a market cap of $30.19 billion, a P/E ratio of 22.41, a price-to-earnings-growth ratio of 1.56 and a beta of 1.21. IQVIA Holdings Inc. has a one year low of $153.01 and a one year high of $247.04. The stock has a fifty day moving average price of $173.39 and a 200 day moving average price of $193.77. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.